# Methotrexate Early Toxicity Monitoring

> **NCT07406230** · NA · NOT_YET_RECRUITING · sponsor: **Assistance Publique Hopitaux De Marseille** · enrollment: 50 (estimated)

## Conditions studied

- Primary Central Nervous System Lymphoma

## Interventions

- **OTHER:** methotrexate plasmatic dosing

## Key facts

- **NCT ID:** NCT07406230
- **Lead sponsor:** Assistance Publique Hopitaux De Marseille
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2027-04
- **Final completion:** 2027-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07406230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07406230, "Methotrexate Early Toxicity Monitoring". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07406230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*